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Dr Richard J. Shemin (Los Angeles, Calif). I, too, want to
thank the Association for the opportunity to comment on this really
detailed and excellent study and presentation. The authors were
able to provide me with a detailed copy of the manuscript so I
have more information than was presented today.870 The Journal of Thoracic and Cardiovascular SurgThe fact that there is a price to pay for complications is well
known to this surgical community, but this study really met the
goal of quantifying the cost in dollars, days, and deaths, as well
as the postdischarge resource use after an isolated mitral valve sur-
gery. As the discussion clearly stated, this comes from an admin-
istrative data set, the Nationwide Inpatient Sample (NIS). This
sample is only 20% of nonfederal hospitals in 37 states and the
use of ICD-9 codes, as has been stated, has major limitations
and clearly does not allow a robust evaluation for risk adjustment
and other analyses that we are used to from the Society of Thoracic
Surgeons (STS) data base. The overall sample in this study was
taken from 2 years—2006 and 2007—more than 16,788 patients.
I was somewhat surprised to find that 10,000-plus patients actually
had concomitant procedures, leaving them with isolated mitral
valve surgery in 6297, and then I was also surprised to find 50%
of them actually had mitral valve repairs as opposed to replace-
ment. I am not sure we would have predicted that was the case.
The inpatient hospital mortality was actually quite good, 4% and
2% in elective cases, and 82% of the patients did not have any
of complications that were studied in this particular study. The
complication rates also of interest did not differ between repair
and tissue replacement or mechanical replacement and a single
complication clearly escalated the outcomes and the end points
such as mortality, length of stay, and cost, and the need for in-
creased resources. Very interesting was the exponential increase
in cost associated with multiple complications. I was really sur-
prised to find that pneumonia and sepsis were your most frequent
complications. I suspect this was because of the study design and
the choice of complications that you included in the study. These
potentially preventable complications can increase the cost of hos-
pitalization by more than $30,000. Cardiac tamponade, which was
the most costly complication in the study increasing the median
cost by $57,000, only occurred in 0.1% of the patients. Therefore,
I assume the ICD-9 codes were not capturing patients going back
to the operating room for bleeding, the use of blood utilization, and
as you mentioned the lack of studying atrial fibrillation, which is
very frequent, or sternal wound infection, which is infrequent
but very costly, is clearly a limitation. Therefore, I think this study
only looks at the tip of the iceberg as far as the true cost of com-
plications after isolated mitral valve surgery. Therefore, the study
challenges us to really improve on the strategies that we need to
incorporate to reduce the costs of taking care of our patients.
Therefore, I have 4 questions for you.
First, do you have any data on the impact of surgical volume at
these various hospitals, whether it be total cardiac surgery volume
or mitral valve surgery volume, on the frequency of the complica-
tions, or the cost?
Dr Iribarne. Thank you, Dr Shemin, for your careful and
thoughtful review of our manuscript.
First, regarding the quality of the data, NIS has a number of at-
tractive features. It is accessible, inexpensive, and easy to use.
Moreover, it contains information on the clinical and economic
data of the patient, as well as information on the institution. Fi-
nally, although crude, the use of ICD-9 codes to extract clinical
information from administrative datasets is a proven and increas-
ingly applied research approach.
However, we agree that this data has all of the limitations asso-
ciated with the use of large claims datasets. For example, as youery c April 2012
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Dpoint out, the incidence of tamponade was clearly underestimated
by this analysis. Further, sepsis was likely overcoded and more
likely overlaps with other types of cardiovascular compromise
and pressor dependence.
Our group is exploring the use of other large data sources to pur-
sue similar questions to those proposed here. These might include
the Centers for Medicare and Medicaid Services (CMS), Thomp-
son-Reuters’ Marketscan data, the University Health System Con-
sortium (UHSC) data, and various statewide quality initiatives.
Finally, in the future, STS data may be linked to costing data,
and this may provide a powerful tool for pursuing these cost
questions.
With regard to the first question, it is possible to capture institu-
tional volume data in the NIS. Other groups have done this and, in
fact, we have explored questions using this data. However, for this
analysis, we did not explore the relationship between volume cost.
I think that this is, however, an important but complex group of
questions that are worth exploring.
Dr Shemin. Clearly, if one does find that to be the case as we
find in many other areas of surgery, you can incorporate and find
best practices that can be taught to others as we look for ways to
find solutions.
The second question has to do with whether or not there is any-
thing in your data set that will allow you to predict the 15% of pa-
tients who would have the complications that you showed us so
that strategies can be targeted to those patients and specific com-
plications and not have a very expensive protocol to try to incorpo-
rate everyone?
Dr Iribarne. Defining the relationship between preoperative
comorbidities and outcomes, including complications and cost,
is possible with this data. We have previously explored this in other
populations, including a single institution’s series of ventricular
assist device patients. We are also interested in exploring the use-
fulness of various severity or comorbid illness tools, including theThe Journal of Thoracic and CaDeyo modification to the Charlston index, the Elixhauser index,
and the 3M APR-DRG, to pursue other questions related to vol-
ume-outcome relationships across levels of patient risk and com-
paring disease-specific therapeutic options across various patient
risk strata.
Dr Shemin. And I have a methodologic question. When you
went ahead and looked at the 20% costs and then you looked at
the total costs by increasing it by a factor of 5, is that technically
correct? As I understand it, there are actually correction values
that come with the nationwide sample that allow you to look at
the total cohort and not necessarily do some arithmetic by increas-
ing 20% to 100% by just multiplying by 5.
Dr Iribarne.You are correct. The NIS assigns a correction fac-
tor to each patient and institution. The cost estimates that we pre-
sented were ranges based on bootstrapped estimates. Therefore,
the estimates are unlikely to differ significantly. Nevertheless,
per your suggestion, the final version of the manuscript uses an
NIS-provided correction factor to calculate this estimate.
Dr Shemin. The final question is, now that you have these data,
what types of things do you think we need to do to reduce this com-
plication rate and better treat these patients?
Dr Iribarne. Thank you for your question. This analysis alone
does nothing to improve outcomes or decrease costs. However, we
hope that it highlights opportunities for improving outcomes, de-
creasing costs, and therefore offering greater value in health
care. As you suggested earlier, as a health care community, we
need to be more aggressive by identifying best practices. We ap-
plaud these efforts, particularly of surgeon-driven statewide efforts
to improve quality, including those in Northern New England, Vir-
ginia, and Washington State. We hope that other regions adopt
similar methods. Further we see an opportunity for similar contin-
uous quality improvement efforts to be based on specific therapies,
such as transplantation, ventricular assist devices, and valvular
therapies.rdiovascular Surgery c Volume 143, Number 4 871
